Related Experiment Videos
Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction
D A Brand1, L N Newcomer, A Freiburger
1Center for Health Care Policy and Evaluation and Medical Services Group, United HealthCare Corporation, Minneapolis, Minnesota, USA.
Insights
Cardiologists show low adherence to beta-blocker guidelines post-myocardial infarction. Only 48% of eligible patients received this life-saving therapy, indicating a significant gap in post-heart attack care.
Area of Science:
- Cardiology
- Pharmacotherapy
- Clinical Practice Guidelines
Background:
- Beta-blocker therapy is proven to reduce reinfarction and mortality after acute myocardial infarction (MI).
- Adherence to American College of Cardiology guidelines for post-MI beta-blocker use is crucial for patient outcomes.
- Analyzing insurance claims provides insights into real-world prescribing patterns.
Purpose of the Study:
- To assess cardiologists' adherence to long-term beta-adrenergic blocker therapy guidelines following acute myocardial infarction.
- To quantify the gap between recommended and actual beta-blocker use in post-MI patients.
Main Methods:
- Retrospective analysis of insurance claims from 17 US health plans.
- Inclusion of 150 cardiologists and 280 eligible post-MI patients (non-revascularized, non-Medicare) from 1992.
- Beta-blocker usage and contraindications identified via insurance claims.
Main Results:
- 43% of cases showed guideline deviations, including errors of commission and omission.
- Only 48% of patients without contraindications received beta-blocker therapy post-discharge.
- Significant underutilization of beta-blockers in eligible post-MI patients was observed.
Conclusions:
- Cardiologists demonstrate low compliance with post-MI beta-blocker guidelines.
- Increased beta-blocker use in eligible patients could potentially prevent approximately 1,900 deaths annually.
- There is a critical need to improve guideline adherence for beta-blocker therapy after myocardial infarction.
Objective:
Our purpose was to measure cardiologists' level of adherence to guidelines for long-term use of beta-adrenergic blocker therapy after acute myocardial infarction.
Background:
Beta-blocker therapy after acute myocardial infarction has been shown to reduce the incidence of reinfarction and associated mortality. To learn about cardiologists' use of this therapy after hospital discharge and their level of adherence to American College of Cardiology guidelines, we analyzed insurance claims from 17 network-model health plans located throughout the United States.
Methods:
The study group included 150 cardiologists who had contracts with one of the health plans and their 280 patients who were plan members (excluding Medicare enrollees) and received inpatient treatment for acute myocardial infarction that did not include revascularization during 1992. These patients accounted for 307 separate hospital admissions. Insurance claims were used to measure beta-blocker usage and to identify possible contraindications.
Results:
Forty-three percent of the cases (131 of 307) involved apparent deviations from the guidelines: 11% of cases (35 of 307) involved possible errors of commission (beta-blocker given in the presence of a contraindication) and 31% (96 of 307) errors of omission (beta-blocker not given in the absence of a contraindication). Of the 185 patients who were eligible for the therapy (no contraindications), only 48% (89 of 185) were treated.
Conclusions:
Cardiologists currently exhibit a low level of compliance with their specialty's guidelines for postinfarction beta-blockade. Slightly fewer than 50% of the study patients who were eligible for treatment actually received a beta-blocker after hospital discharge. This result, combined with the drug's known level of effectiveness in preventing recurrent myocardial infarction, suggests that increased use could avert approximately 1,900 deaths annually nationwide.